TG
TG Therapeutics
TGTX·NASDAQNew York NYFounded 2012250 employees
Mid CapbiotechPublicHematologyImmunology
Platform: Anti-CD20
Market Cap
$5B
All Drugs
3
Clinical Trials
8
Failed / Terminated
1
FDA Approved
1
Stock Price & Catalysts (TGTX)
Loading TGTX stock data...
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Fixaosocimab | TGT-1729 | Phase 2/3 | 2 | SOS1 | CRCPTSD | ||
| Tirarelsin | TGT-3379 | NDA/BLA | 2 | CD19 | RSVT2D | ||
| Capirapivir | TGT-6161 | Approved | 4 | JAK2 | PVRB |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (7)